Kestra Private Wealth Services LLC Has $946,000 Holdings in Sanofi (NASDAQ:SNY)

Kestra Private Wealth Services LLC trimmed its position in shares of Sanofi (NASDAQ:SNY - Free Report) by 23.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 19,604 shares of the company's stock after selling 5,971 shares during the period. Kestra Private Wealth Services LLC's holdings in Sanofi were worth $946,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of SNY. Synergy Asset Management LLC acquired a new stake in Sanofi in the fourth quarter valued at about $25,000. Northwest Investment Counselors LLC acquired a new stake in shares of Sanofi in the 3rd quarter valued at approximately $29,000. Concord Wealth Partners boosted its stake in shares of Sanofi by 157.8% in the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company's stock valued at $34,000 after purchasing an additional 363 shares in the last quarter. Fortitude Family Office LLC grew its holdings in shares of Sanofi by 708.6% during the 3rd quarter. Fortitude Family Office LLC now owns 752 shares of the company's stock valued at $43,000 after purchasing an additional 659 shares during the last quarter. Finally, Sunbelt Securities Inc. increased its position in Sanofi by 72.1% during the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company's stock worth $43,000 after purchasing an additional 313 shares in the last quarter. 14.04% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts have weighed in on SNY shares. Sanford C. Bernstein raised shares of Sanofi to a "strong-buy" rating in a research note on Thursday, January 30th. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a "sell" rating to a "hold" rating in a research report on Thursday, January 30th. Finally, StockNews.com downgraded Sanofi from a "buy" rating to a "hold" rating in a research report on Thursday, December 12th. Two investment analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Buy" and a consensus price target of $60.00.

Sanofi Trading Up 0.9 %

Shares of Sanofi stock traded up $0.51 during trading on Monday, hitting $54.50. The company's stock had a trading volume of 1,806,359 shares, compared to its average volume of 2,648,729. The stock has a market cap of $138.31 billion, a price-to-earnings ratio of 21.89, a price-to-earnings-growth ratio of 0.99 and a beta of 0.57. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 0.74. Sanofi has a 52 week low of $45.22 and a 52 week high of $58.97. The stock has a 50-day moving average price of $50.42 and a two-hundred day moving average price of $52.47.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting the consensus estimate of $0.70. Sanofi had a return on equity of 25.58% and a net margin of 12.77%. Equities research analysts anticipate that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.